{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-332802","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2026-08-04T20:09:52+00:00","discovered_at":"2026-08-04T20:11:03.450144+00:00","generated_at":"2026-08-04T20:11:33.493619+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ultragenyx Q2 revenue $214M, net loss narrows to $0.90/share; reaffirms 2026 guidance","bullets":["Q2 total revenue $214M (up 28% YoY); Crysvita $156M, Dojolvi $27M, Evkeeza $21M, Mepsevii $10M.","Net loss $92M ($0.90/share) vs $115M ($1.17) in Q2 2025; operating expenses $289M.","Reaffirms FY2026 revenue guidance $730M-$760M; combined R&D/SG&A flat to slightly down vs 2025; on track for profitability in 2027.","Upcoming catalysts: PDUFA for DTX401 (Aug 23) and UX111 (Sep 19); GTX-102 Phase 3 data in Sep/Oct 2026.","Cash $436M; net cash used in operations $97M in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-332802","json":"https://secwatch.observer/filing/0001193125-26-332802.json","markdown":"https://secwatch.observer/filing/0001193125-26-332802.md","text":"https://secwatch.observer/filing/0001193125-26-332802.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/0001193125-26-332802-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:11:33.493619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}